FDA Consumer Health Information Updates: New Web Videos Educate Consumers about Food and Medical Product Safety
Excerpt from:
FDA Consumer Health Information Updates: New Web Videos Educate Consumers about Food and Medical Product Safety
The U.S. Food and Drug Administration today announced the availability of the first draft guidance for industry on Risk Evaluation and Mitigation Strategies or REMS, which are required for certain drugs or biologics.
View original here:
FDA Issues Draft Guidance on Risk Evaluation and Mitigation Strategies
The U.S. Food and Drug Administration today announced the availability of the first draft guidance for industry on Risk Evaluation and Mitigation Strategies or REMS, which are required for certain drugs or biologics.
Go here to see the original:
FDA Issues Draft Guidance on Risk Evaluation and Mitigation Strategies
The U.S. Food and Drug Administration today issued its Strategic Plan for Risk Communication, which outlines the agency’s efforts to disseminate more meaningful public health information.
Read the original:
FDA Issues Strategic Plan for Risk Communication
United States Attorney Michael L. Levy today announced the filing of an Information1 against Select Veal Feeds, Inc., and its owner Wayne A. Marcho, charging the defendants with one count of misbranding, in violation of the Food, Drug and Cosmetic Act
Excerpt from:
U.S. Attorney News Release: Veal Company Charged in Case of Tainted Feed
Nationwide recall of Neocate Infant Specialized Formula, Lot # P91877, due to a manufacturing error that resulted in protein levels lower than that declared on the label.
Read more:
Neocate Infant Specialized Formula - Recall
Nationwide recall of Neocate Infant Specialized Formula, Lot # P91877, due to a manufacturing error that resulted in protein levels lower than that declared on the label.
Here is the original post:
Neocate Infant Specialized Formula - Recall
W. Scott Harkonen, M.D., and the former CEO of InterMune, Inc., was convicted of wire fraud for the creation and dissemination of false and misleading information about the efficacy of InterMune’s drug Actimmune (Interferon gamma-1b) as a treatment for idiopathic pulmonary fibrosis (”IPF”), the United States Attorney’s Office for the Northern District of California and the Civil Division of the United States Department of Justice announced.
See the original post:
U.S. Attorney News Release: W. Scott Harkonen, Former Biotech CEO, Convicted of Wire Fraud